Brief: Allena Pharmaceuticals Receives Fast Track Designation From FDA For The Development Of Hyperuricemia Drug Candidate

Allena Pharmaceuticals

03/11/2021 12:20

Nov 3 (Reuters) - Allena Pharmaceuticals Inc  ALNA.O :
    * ALLENA PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION
FROM FDA
FOR THE DEVELOPMENT OF ALLN-346 FOR CHRONIC TREATMENT OF
HYPERURICEMIA IN PATIENTS WITH GOUT AND ADVANCED CHRONIC KIDNEY
DISEASE
    * ALLENA PHARMACEUTICALS INC - INITIAL BIOACTIVITY DATA
EXPECTED
IN LATE 2021 OR EARLY 2022
    * ALLENA PHARMACEUTICALS INC - TWO PHASE 2A STUDIES
CURRENTLY
ENROLLING PATIENTS WITH HYPERURICEMIA AND CKD

Source text for Eikon:  ID:nGNXH5D9T 
Further company coverage:  ALNA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))